Vol 5, No 18 (September 19, 2017): Annals of Translational Medicine (Focus on "Emerging Uses of Biomarkers in Lung Cancer Management")

Preface

Emerging uses of biomarkers in lung cancer management
Balazs Halmos, Benjamin Levy
Annals of Translational Medicine
 2017;
5
(18)
:370
(September 2017)
PDF Pages: 370 Full Text (2158) Open Access Get Permission

Review Article

Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs
Howard West
Annals of Translational Medicine
 2017;
5
(18)
:371
(September 2017)
PDF Pages: 371 Full Text (1883) Open Access Get Permission
Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer
Kah Weng Lau, Claudia Seng, Tony K. H. Lim, Daniel S. W. Tan
Annals of Translational Medicine
 2017;
5
(18)
:372
(September 2017)
PDF Pages: 372 Full Text (3070) Open Access Get Permission
Relevance of genetic alterations in squamous and small cell lung cancer
Joshua K. Sabari, Paul K. Paik
Annals of Translational Medicine
 2017;
5
(18)
:373
(September 2017)
PDF Pages: 373 Full Text (2811) Open Access Get Permission
Prognostic and predictive biomarkers post curative intent therapy
Rebecca Feldman, Edward S. Kim
Annals of Translational Medicine
 2017;
5
(18)
:374
(September 2017)
PDF Pages: 374 Full Text (5322) Open Access Get Permission

Editorial

PD-L1 as a biomarker in NSCLC: challenges and future directions
Matthen Mathew, Rachael A. Safyan, Catherine A. Shu
Annals of Translational Medicine
 2017;
5
(18)
:375
(September 2017)
PDF Pages: 375 Full Text (8215) Open Access Get Permission

Review Article

Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
Khinh Ranh Voong, Josephine Feliciano, Daniel Becker, Benjamin Levy
Annals of Translational Medicine
 2017;
5
(18)
:376
(September 2017)
PDF Pages: 376 Full Text (8941) Open Access Get Permission
Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance
Shirin Attarian, Numa Rahman, Balazs Halmos
Annals of Translational Medicine
 2017;
5
(18)
:377
(September 2017)
PDF Pages: 377 Full Text (2993) Open Access Get Permission
Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges
Vamsidhar Velcheti, Nathan A. Pennell
Annals of Translational Medicine
 2017;
5
(18)
:378
(September 2017)
PDF Pages: 378 Full Text (4943) Open Access Get Permission
Circulating DNA in EGFR-mutated lung cancer
Aditi P. Singh, Shenduo Li, Haiying Cheng
Annals of Translational Medicine
 2017;
5
(18)
:379
(September 2017)
PDF Pages: 379 Full Text (5916) Open Access Get Permission
Emerging uses of circulating tumor DNA in advanced stage nonsmall cell lung cancer
Melina Marmarelis, Jeffrey C. Thompson, Charu Aggarwal, Tracey L. Evans, VErica Carpenter, Roger B. Cohen, Corey J. Langer, Joshua Bauml
Annals of Translational Medicine
 2017;
5
(18)
:380
(September 2017)
PDF Pages: 380 Full Text (4535) Open Access Get Permission

Erratum

Erratum to epigenetics of colorectal cancer: emerging circulating diagnostic and prognostic biomarkers
Editorial Team
Annals of Translational Medicine
 2017;
5
(18)
:381
(September 2017)
PDF Pages: 381 Full Text (1211) Open Access Get Permission

Retraction

Retraction to cardiotoxicity of cancer chemotherapy: identification, prevention and treatment
Editorial Team
Annals of Translational Medicine
 2017;
5
(18)
:382
(September 2017)
PDF Pages: 382 Full Text (2498) Open Access Get Permission

Disclosure:

The series “Emerging Uses of Biomarkers in Lung Cancer Management” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding. Balazs Halmos and Benjamin Levy served as the unpaid Guest Editors for the series.